Skip to Content

'
James W. Welsh, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 Dartmouth School of Medicine, Hanover, NH, MD, Medicine
1997 University of California, Davis, CA, BS, Genetics

Postgraduate Training

7/2004-6/2008 Clinical Residency, Radiation Oncology, The University of Arizona Health Sciences Center, Tucson, AZ
7/2003-6/2004 Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

8/2008 American Board of Radiology

Experience/Service

Other Appointments/Responsibilities

Research Associate, Dartmouth Hitchock Medical Center, Lebanon, NH, 7/2003-12/2003
Research Associate, Genetech, Inc. - Division of Molecular Oncology, San Francisco, CA, 5/1997-8/1999
Researach Assistant, U. C. Davis Medical School, Davis, CA, 9/1996-4/1997

Honors and Awards

2008 2008 Honorarium, Multidisciplinary Symposium in Thoracic Oncology, Chicago, ASTRO
2006 First Place Abstract, Los Angeles Radiological Society Annual Meeting, 2006, Los Angeles Radiological Society
2005 ASTRO Translational Research Symposium Travel Grant, ASTRO

Selected Publications

Peer-Reviewed Original Research Articles
1. Turner LM, Howard JA, Dehghanpour P, Barrett RD, Rebueno N, Palmer M, Vedam S, Klopp A, Komaki R, Welsh JW. Exploring the Feasibility of Dose Escalation with IMRT and the Effects on Normal Tissue Structures for Thoracic Malignancies. Medical Dosimetry. In Press.
2. Olsen C, Welsh J, Schefter T, Franklin M, Kavanagh B. Histopathological observations in human liver parenchyma following high-dose stereotactic body radiation therapy. International Journal of Radiation Oncology Biology Physics. In Press.
3. Welsh, J, Mahadevan D, Bearss D, Stea, B. Sensitization of a GBM cell line by MP470, a novel C-Met antagonist. Preparation Molecular Cancer Therapeutics. In Press.
4. Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel R. Rad 51 protein expression and survival in patients with glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics 74(4):1251-5, 2009.
5. Nguyen NP, Borok TL, Welsh J, Vinh-Hung V. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax 64:174-178, 2009.
6. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE , Schefter TE. Microscopic and Macroscopic Tumor and Parenchymal Effects of Liver Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 73(5):1414-24, 11/2008.
7. Nguyen NP, Vos P, Lee H, Borok TL, Karlsson U, Martinez T, Welsh J, Cohen D, Hamilton R, Nguyen N, Nguyen LM, Vinh-Hung V. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75(3-4):186-191, 10/2008.
8. Ellsworth R, Welsh J, Mahadevan D, Bearrs D, Hsieh D, Fjerstad HK, Marsella M, Sanan A, Badrudojja M, Stea B. The Radiosensitizing Effects of a Novel Tyrosine Kinase Inhibitor, Mp470 in Glioblastoma Multiforme Stem Cells. International Journal of Radiation Oncology, Biology, Physics 72(1):s714-s715, 9/2008.
9. nguyen NP, Garland L, Welsh JW, hamilton R, Cohen D, Vincent VH. Can Sterotactic franctionated radiation rherapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treatment Reviews 34:719-727, 7/2008.
10. Welsh J, Abhay S, Gabayan AJ, Green, SB, Lustig R, Burri S, Kwong, E, Baldassarre S. GliaSite Radiotherapy Boost as Part of Initial Treatment of Malignant Gliomas: A Multi-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 68(1):159-165, 2007, 2007.
11. Welsh J, Levine PD. WISP-1 is a Wnt-1 and beta-catenin-responsive oncogene. Genes & Development. 14(5):585-95, 2000.
12. Swanson PD, Welsh J, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proceedings of the National Academy of Sciences of the United States of America. 95(25):14717-22, 1998, 1998.
13. Trevor, KT, Combs, D, Al-Obeidi, A, Mahadevan, D, Welsh, JW, Bearss, D, Cranmer, LD. MP470, A novel agent for the treatment of synovial sarcoma. Submitted.
14. Nguyen NP, Garland L, Borok TL, Welsh J, Hamilton R, Cohen D, Vincent V-H. Pattern of Failure Following Chemoradiation for Locally Advanced Non-Small Cell Lung cancer: Implications for Future Clinical Trials. Submitted.

Abstracts
1. Ron Ellsworth, James Welsh, Rachit Kumar, Kyle Fjerstad, Sylvan Green, Raymond Nagle, Baldassarre Stea. CD133 expression before and after radiation in Glioblastoma Multiforme. AACR 2008, 2008.
2. Welsh J, Mahadevan D, Dougherty G, Stea B. A c-MET receptor Tyrosine Kinase inhibitor radiosensitizes Glioblastoma cells by reducing dsDNA repair, mediated through decreased Rad-51. Radium Society, 2007, 2007.
3. Welsh J, Garland L, Stea BD. A Phase II Study to Determine the Efficacy of Tarceva (Erlotinib Hydrochloride) with Concurrent Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer. World Lung South Korea, 2007, 2007.
4. Kumar R, Welsh J, Nagle RB, Green S, Stea BD. Association Between Rad-51 Levels and Survival In Patients with Glioblastoma Multiforme Treated With Radiation Therapy. ASTRO 2007, 2007.
5. Welsh J, Gabayan A, Sanan A, Stea B. GliaSite dose escalation trial for treating Glioblastoma Multiforme. International Conference of Translational Radiotherapy, 2007, 2007.
6. Schefter TE, Welsh J, Gaspar L, Kavanagh B. Normal liver V30% and mean liver dose predicts the maximum normal liver volume reduction after Stereotactic Body Radiation Therapy (SBRT). ASTRO 2007 69(3), 2007.
7. Welsh J, Mahadevan D, Bearss D, Stea B. Sensitization of a GBM cell line by MP470, a novel C-Met antagonist. ASTRO, 2007, 2007.
8. Welsh J, Mahadevan D, Dougherty G, Stea B. c-MET Inhibition Radiosensitizes Melanoma by Inhibiting Double Strand DNA Repair. ASTRO and EORTC Annual Meeting, 2006., 2006.
9. Watchman C, Hamilton R, Welsh J. Implanted Marker Movements During Prostate IMRT. AAPM Annual Meeting, 2006. Watchman C, Hamilton R, Welsh J., 2006.
10. Welsh J, Gabayan A, Sanan A, Hass M, Burri S, Bishop M, Stea B. GliaSite Radiotherapy Boost as Part of Initial Treatment of Malignant Gliomas: A Multi-institutional Analysis. ASTRO 2005, Radiological Society, 2006, 2005.

Grant & Contract Support

Title: c-Met Antagonist (MK-2461/8033) as a Potential Radiosensitizer in Non-Small Cell Lung Cancer
Funding Source: Merck and Company
Role: Principal Investigator
Duration: 5/22/2009 - 11/30/2011
 
Title: Phase II investigator initiated trials of Erlotinib plus radiation in patients with brain metastasis from Non-Small Cell Lung Cancer.
Funding Source: OSI Pharmaceuticals, Inc.
Role: Principal Investigator
Duration: 2/26/2009 - 2/26/2012
 
Title: Testing of various small molecules in combination with radiation, in melanoma, glioblastoma, and lung cancer
Funding Source: SuperGen, Inc.
Role: Principal Investigator
Duration: 1/2007 - 1/2008
 
Title: Start up funds to test and evaluate various bilogically targeted radiation sensitizers for the treatment of Glioblastoma Multiforme.
Funding Source: Arizona Cancer Center
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2006

Last updated: 9/3/2009